{"id":"NCT04851873","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)","officialTitle":"A Phase IIIb, Open-label, Single-arm, Single-dose, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Gene Replacement Therapy With Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-09-08","primaryCompletion":"2023-06-13","completion":"2023-06-13","firstPosted":"2021-04-21","resultsPosted":"2024-01-05","lastUpdate":"2024-10-09"},"enrollment":24,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Spinal Muscular Atrophy"],"interventions":[{"type":"GENETIC","name":"OAV101","otherNames":[]}],"arms":[{"label":"OAV101","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety, tolerability and efficacy of intravenous administration of OAV101 (AVXS-101) in patients with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene weighing ≥ 8.5 kg and ≤ 21 kg, over a 12 month period.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) by Weight Bracket","timeFrame":"Up to Month 12","effectByArm":[{"arm":"OAV101 1.1e14 vg/kg 8.5-13 kg","deltaMin":7,"sd":null},{"arm":"OAV101 1.1e14 vg/kg >13-17 kg","deltaMin":8,"sd":null},{"arm":"OAV101 1.1e14 vg/kg >17-21 kg","deltaMin":9,"sd":null},{"arm":"OAV101 1.1e14 vg/kg Overall","deltaMin":24,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":13,"countries":["United States","Australia","Belgium","Canada","France","Italy","Portugal","Taiwan","United Kingdom"]},"refs":{"pmids":["39804575"],"seeAlso":["https://medinfo.novartis.com/gene-therapies/","https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1937"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":7},"commonTop":["Vomiting","Pyrexia","Nausea","Upper respiratory tract infection","Hypertransaminasaemia"]}}